Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
KAZIA THERAPEUTICS LTD (KZIA) received an amended Schedule 13G/A indicating that investor Jorey Chernett beneficially owns a significant stake in the company’s American Depositary Shares (ADS).
As of the close of business on August 19, 2026, Chernett beneficially owned 2,339,009 ADS, representing 19.6% of the ADS class, based on 11,926,899 ADS outstanding as of the same date. Chernett reports sole voting and sole dispositive power over all 2,339,009 ADS, with no shared voting or dispositive power.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of 575,778 American Depositary Shares (ADSs) of Kazia Therapeutics Limited, representing 4.9% of this ADS class. Each ADS represents five-hundred Ordinary Shares of Kazia.
The reported position includes 179,577 ADSs that may be acquired within 60 days pursuant to warrants, which are subject to a 4.99% beneficial ownership limitation on conversion. The 4.9% figure is calculated using a total of 11,515,568 ADSs, comprising 11,335,991 ADSs outstanding as of December 11, 2025 plus 179,577 ADSs issuable upon warrant exercise, as disclosed in Kazia’s Form F-1. Ikarian Capital manages a master fund and separately managed accounts that are the record owners, and both Ikarian Capital and Mr. Shahrestani disclaim being a “group” or ultimate beneficial owners beyond what may be deemed under Section 13(d) or 13(g).
Kazia Therapeutics Limited is reported to have 264,980,500 Ordinary Shares beneficially owned by Lynwood Opportunities Master Fund, Lynwood Capital Management Inc., and Ben Shapiro, as of June 30, 2026. This represents 4.6% of the 5,713,449,734 Ordinary Shares outstanding as of March 12, 2026.
The shares are held through the issuer’s American Depositary Shares, with each ADS representing 500 Ordinary Shares. Each reporting person has sole voting and dispositive power over the reported shares and confirms ownership of 5 percent or less of the class. The reporting persons disclaim beneficial ownership beyond the shares directly held by each.
Kazia Therapeutics Limited filed a prospectus supplement covering 266,666 American Depositary Shares (ADSs), representing 133,333,000 ordinary shares, and updating its existing Form F-1 prospectus by incorporating a new Form 6-K.
The incorporated Form 6-K includes a press release describing a provisional patent application for a novel perioperative therapeutic strategy using paxalisib to prevent metastatic recurrence in high-risk early-stage triple-negative breast cancer. In a preclinical TNBC model, standard therapy followed by adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%, while ex vivo studies showed 100% disruption of circulating tumor cell clusters. The company is evaluating expansion of paxalisib development into earlier-stage TNBC. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $12.21 per ADS on July 27, 2026.
Kazia Therapeutics Limited is updating its existing Form F-1 prospectus through a prospectus supplement covering 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares. The ADSs trade on Nasdaq under “KZIA,” with a last reported price of $12.21 per ADS on July 27, 2026.
Through an attached Form 6-K, the company reports filing a provisional patent application for a novel perioperative strategy using its lead asset, paxalisib, aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer. Preclinical perioperative studies showed a 95% reduction in residual disease and local recurrence and a 40% reduction in lung metastatic burden when standard therapy was followed by adjuvant paxalisib, while ex vivo studies showed 100% disruption of circulating tumor cell clusters.
Kazia Therapeutics Limited filed a prospectus supplement updating a Form F-1 registration covering 95,110 American Depositary Shares (ADSs), representing 47,555,000 ordinary shares. The supplement incorporates a July 28, 2026 report describing new scientific developments into the offering materials.
The company reports filing a provisional patent for a novel perioperative therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer. In a TNBC preclinical model, standard treatment followed by adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%. Ex vivo studies on patient tumor samples showed paxalisib fully disrupted (100%) circulating tumor cell clusters. These data, together with observations from an ongoing Phase Ib metastatic TNBC study, are presented as supporting further development of paxalisib across multiple disease stages.
Kazia Therapeutics Limited is updating an existing Form F-1 prospectus covering 10,700,211 American Depositary Shares (ADSs), each representing underlying ordinary shares, by incorporating a new Form 6-K filed on July 28, 2026. The ADSs trade on Nasdaq under the symbol KZIA, and the last reported price on July 27, 2026 was $12.21 per ADS.
The attached report describes a new provisional patent application for a novel therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer using paxalisib. In a perioperative TNBC model, standard therapy followed by paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%, and ex vivo patient samples showed 100% disruption of circulating tumor cell clusters. These preclinical and translational findings, together with observations from an ongoing Phase Ib study in metastatic TNBC, are cited as support for broadening paxalisib development across multiple stages of disease.
Kazia Therapeutics Limited filed a provisional patent application for a novel perioperative therapeutic strategy intended to prevent metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer (TNBC).
The strategy is supported by preclinical data in a TNBC model where standard treatment followed by adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%. Ex vivo studies on tumor samples from high-risk early-stage TNBC patients showed paxalisib disrupted 100% of detected circulating tumor cell clusters. Preliminary findings from an ongoing Phase Ib study of paxalisib with pembrolizumab and chemotherapy in advanced metastatic TNBC, including objective tumor responses and CTC cluster disruption, further support continued development of paxalisib across multiple stages of TNBC. Paxalisib is Kazia’s lead PI3K/Akt/mTOR inhibitor and has been evaluated in multiple clinical trials across several central nervous system and oncology indications, with various FDA designations including Orphan Drug and Fast Track.
Kazia Therapeutics director Steven R. S. Coffey reported a grant of 100,000 employee stock options over ADSs. The options carry an exercise price of $9.10 per ADS, were granted for no consideration, vest on January 8, 2027, and expire on January 8, 2029. Following this award, he holds 100,000 derivative securities directly.
KAZIA THERAPEUTICS LTD Chief Executive Officer John E. Friend II received new equity compensation awards in the form of restricted share units and stock options tied to the company’s ADSs. These are grants, not open-market purchases.
The awards include 150,000 restricted share units, each representing a contingent right to receive one ADS, and 500,000 employee stock options with an exercise price of $6.78 per ADS. One-third of both the RSUs and options vest on January 8, 2027, with the remaining two-thirds vesting in equal yearly tranches on each anniversary thereafter. The options were granted for no cash consideration and expire on January 8, 2029.